Bevacizumab, a monoclonal antibody against VEGF-A, has also been tested in a phase II trial in cases of recurrent grade 3 meningiomas with a progression-free survival rate of 46%, hence suggesting anti-tumor activity [140]. This evidence concerns the gene VEGFA and neoplasm.